Cipla signs agreement with Merck for Molnupiravir
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Subscribe To Our Newsletter & Stay Updated